Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.
Amgen and UCB have demonstrated the efficacy of their osteoporosis treatment romosozumab in men in the Phase III BRIDGE study. This follows Phase III FRAME data in women which will form the basis of a US filing later this year.
"While the focus of managing osteoporosis is often on women, osteoporosis in men is also a serious health issue," said...
Create an account to read this article
Already a subscriber?
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
The osteogenesis imperfecta drug stumbled in a second interim analysis.
The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.
Biogen hopes to move directly from Phase I to Phase III with salanersen, a higher-potency therapy that uses the same mechanism of action as Spinraza.
